

S4 vs Pathway Expression

	1	0			
S4			IC(Δ)	P-val	FDR
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL			0.716(0.011)	2.62e-06	3.60e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL			0.658(0.020)	2.62e-06	3.60e-05
AUNG_GASTRIC_CANCER			0.657(0.017)	2.62e-06	3.60e-05
HUANG_DASATINIB_RESISTANCE_DN			0.653(0.015)	2.62e-06	3.60e-05
TOMLINS_PROSTATE_CANCER			0.640(0.020)	2.62e-06	3.60e-05
WATANABE_COLON_CANCER_MSI_VS_MSS_DN			0.638(0.016)	2.62e-06	3.60e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP			0.638(0.019)	2.62e-06	3.60e-05
NAKAMURA_ADIPOGENESIS_LATE			0.638(0.013)	2.62e-06	3.60e-05
SANSOM_APC_TARGETS_UP			0.635(0.018)	2.62e-06	3.60e-05
NADELLA_PRKAR1A_TARGETS			0.631(0.016)	2.62e-06	3.60e-05
PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD			0.628(0.016)	2.62e-06	3.60e-05
WALLACE_PROSTATE_CANCER			0.628(0.014)	2.62e-06	3.60e-05
DOANE_BREAST_CANCER_CLASSES			0.626(0.017)	2.62e-06	3.60e-05
LIU_PROSTATE_CANCER			0.622(0.020)	2.62e-06	3.60e-05
KOBAYASHI_EGFR_SIGNALING_6HR			0.620(0.019)	2.62e-06	3.60e-05
REN_ALVEOLAR_RHABDOMYOSARCOMA			0.619(0.020)	2.62e-06	3.60e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP			0.614(0.014)	2.62e-06	3.60e-05
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2			0.614(0.019)	2.62e-06	3.60e-05
WANG_RESPONSE_TO_BEXAROTENE			0.612(0.019)	2.62e-06	3.60e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL			0.611(0.015)	2.62e-06	3.60e-05
SERVITJA_ISLET_HNF1A_TARGETS			-0.647(0.014)	2.62e-06	1.38e-05
PETROVA_PROX1_TARGETS_DN			-0.649(0.016)	2.62e-06	1.38e-05
HUANG_DASATINIB_RESISTANCE_UP			-0.650(0.019)	2.62e-06	1.38e-05
NGO_MALIGNANT_GLIOMA_1P_LOH			-0.651(0.014)	2.62e-06	1.38e-05
ZHU_SKIL_TARGETS_UP			-0.651(0.018)	2.62e-06	1.38e-05
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY			-0.652(0.016)	2.62e-06	1.38e-05
JEON_SMAD6_TARGETS			-0.652(0.014)	2.62e-06	1.38e-05
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN			-0.652(0.021)	2.62e-06	1.38e-05
SENESE_HDAC2_TARGETS_UP			-0.654(0.016)	2.62e-06	1.38e-05
SARTIPY_BLUNTED_BY_INSULIN_RESISTANCE_UP			-0.656(0.015)	2.62e-06	1.38e-05
LEF1_UP.V1			-0.659(0.015)	2.62e-06	1.38e-05
ITO_PTTG1_TARGETS_DN			-0.668(0.014)	2.62e-06	1.38e-05
GROGER_EMT_UP			-0.668(0.014)	2.62e-06	1.38e-05
REACTOME_PYRIMIDINE_CATABOLISM			-0.669(0.019)	2.62e-06	1.38e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN			-0.669(0.012)	2.62e-06	1.38e-05
WOO_LIVER_CANCER_RECURRENCE			-0.673(0.012)	2.62e-06	1.38e-05
HUANG_DASATINIB_RESISTANCE			-0.678(0.020)	2.62e-06	1.38e-05
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE			-0.688(0.011)	2.62e-06	1.38e-05
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL			-0.693(0.011)	2.62e-06	1.38e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN			-0.701(0.014)	2.62e-06	1.38e-05